KYNTRA BIO, INC. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
Kyntra Bio, Inc. filed a Form 8-K on October 6, 2026, reporting Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates the company has received a delisting notice, though the specific exchange, rule violated, cure period, and remediation details are not provided in the extracted text available.
Why this rating
Delisting threat is business-changing for any public company; relative to $21M market cap, loss of public listing status is existential risk.
Extracted items
Tradability signal
NO TRADE
No trade: negative news, but this cell's evidence is too weak. Similar past filings (16 in this cell) moved +0.75% in the called direction over 4 hrs; shrunk for sample size that's a +0.29% edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $5.96 ▲ 1.88% | at our read · unknown $5.85 | +10 min · unknown $5.96 ▲ 1.97% | +30 min · unknown $5.96 ▲ 1.97% | +1 hr · unknown $5.91 ▲ 1.03% | +4 hrs · unknown $6.16 ▲ 5.30% |
The stock had already moved -1.85% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.